美沙拉嗪联合益生菌治疗炎症性肠病临床疗效观察

摘要

目的：探讨美沙拉嗪联合益生菌治疗炎症性肠病的疗效。方法：采用回顾性分析方法，随机选取我院2010年3月至2012年9月收治的42例采用美沙拉嗪治疗和42例采用美沙拉嗪联合益生菌方法治疗的炎症性肠病患者的临床资料进行分析，根据治疗方法的不同分为联合组和对照组，比较两组在治疗8周时间后的内镜复查效果、最终临床疗效和不良反应情况。结果：治疗8周后内镜复查联合组总有效率为90．48％，对照组为80．95％；临床治疗效果联合组总有效率92．86％，对照组为30．95％；不良反应联合组发生5例，对照组发生23例；两组内镜复查效果、临床效果和不良反应发生情况对比差异均无统计学意义（ P＞0．05）。结论：美沙拉嗪联合益生菌治疗炎症性肠病具有很好的效果，值得临床推广应用。treatment and compared the two groups after 8 weeks of treatment effect of endoscopy review ， the final clini-cal efficacy and adverse reactions ．Result：After 8 weeks ， the total effective rate of combination group and was 90．48％and 80．95％and respectively；The total effective rate of clinical outcomes in combination group and the control group was 92．86％and 30．95％；Adverse reactions occurred five cases of the combined group and 23 cases in control group；groups endoscopic review effects ， clinical efficacy and adverse events were not significantly different compared between two groups ．Conclusion： Mesalazine combined probiotics for the treatment of inflammatory bowel disease has a good effect ， worthy of clinical application ．%Objective:To investigate the efficacy of mesalazine combined probiotics inflammatory bowel disease .Method: Take retrospective analysis method to analyze clinical data of 42 IBD using mesalazine treatment and 42 with mesalazine combined probiotics method which randomly selected from March 2010 to September 2012.Divided into control groups and combination group according to the different methods of treatment and compared the two groups after 8 weeks of treatment effect of endoscopy review , the final clinicalefficacy and adverse reactions.Result: After 8 weeks, the total effective rate of combination group andwas 90.48%and 80.95%and respectively; The total effective rate of clinical outcomes in combination groupand the control group was 92.86%and 30.95%; Adverse reactions occurred five cases of the combined groupand 23 cases in control group; groups endoscopic review effects, clinical efficacy and adverse events were notsignificantly different compared between two groups.Conclusion: Mesalazine combined probiotics for thetreatment of inflammatory bowel disease has a good effect, worthy of clinical application.